These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 29187883)
1. Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. Cui S; Su X; Dong L; Qian J; Ye L; Zhang T; Fu H; Han H; Huang J; Yao Y; Gu Y; Jiang L J Cancer; 2017; 8(19):4075-4082. PubMed ID: 29187883 [No Abstract] [Full Text] [Related]
2. Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells. Cui S; Dong L; Qian J; Ye L; Jiang L J Cancer; 2018; 9(1):129-134. PubMed ID: 29290777 [No Abstract] [Full Text] [Related]
3. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872 [TBL] [Abstract][Full Text] [Related]
4. Dynamic changes in PD-L1 expression and CD8 Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259 [TBL] [Abstract][Full Text] [Related]
5. High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples. Zhang W; Cao Z; Gao C; Huang Y; Wu C; Zhang L; Hou L Transl Cancer Res; 2020 Oct; 9(10):5819-5828. PubMed ID: 35117196 [TBL] [Abstract][Full Text] [Related]
6. Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy. Wei Z; Zhan X; Fan L; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y; Li Q Int J Hyperthermia; 2018; 35(1):591-598. PubMed ID: 30307348 [TBL] [Abstract][Full Text] [Related]
7. PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. He Y; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Yu H; Zhou C; Hirsch FR Med Sci Monit; 2017 Mar; 23():1208-1216. PubMed ID: 28275222 [TBL] [Abstract][Full Text] [Related]
8. Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression. Lin Z; Gu J; Cui X; Huang L; Li S; Feng J; Liu B; Zhou Y J Cancer; 2019; 10(1):211-222. PubMed ID: 30662542 [No Abstract] [Full Text] [Related]
9. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951 [TBL] [Abstract][Full Text] [Related]
10. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis. Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017 [TBL] [Abstract][Full Text] [Related]
11. Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. Zajac M; Ye J; Mukhopadhyay P; Jin X; Ben Y; Antal J; Gupta AK; Rebelatto MC; Williams JA; Walker J PLoS One; 2020; 15(4):e0231936. PubMed ID: 32339189 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519 [TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients. Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578 [TBL] [Abstract][Full Text] [Related]
14. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602 [TBL] [Abstract][Full Text] [Related]
15. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8 Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272 [TBL] [Abstract][Full Text] [Related]
16. Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer. Bae SB; Cho HD; Oh MH; Lee JH; Jang SH; Hong SA; Cho J; Kim SY; Han SW; Lee JE; Kim HJ; Lee HJ J Breast Cancer; 2016 Sep; 19(3):242-251. PubMed ID: 27721873 [TBL] [Abstract][Full Text] [Related]
17. Galectin-9 in non-small cell lung cancer. He Y; Jia K; Dziadziuszko R; Zhao S; Zhang X; Deng J; Wang H; Hirsch FR; Zhou C Lung Cancer; 2019 Oct; 136():80-85. PubMed ID: 31454748 [TBL] [Abstract][Full Text] [Related]
18. CD39: the potential target in small cell lung cancer. Chen S; Wu S; Zhang L; Zhang W; Liu Y; Chen B; Zhao S; Li W; Sun C; Wang L; Jia K; Wang H; Chen P; Wu C; Zhu J; He Y; Zhou C Transl Lung Cancer Res; 2020 Aug; 9(4):1483-1495. PubMed ID: 32953520 [TBL] [Abstract][Full Text] [Related]